Top Markets
#1 Helium Helium +47.34%
#2 TENDIES TENDIES +43.82%
#3 Pons Pons +38.81%
#4 UnifAI Network UnifAI Network +18.28%
#5 Seeker Seeker +16.90%
#6 Songbird Songbird +15.77%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +10.42%
#8 DAPPOS DAPPOS +10.15%
#9 OSK OSK +10.10%
#10 Bounce Bounce +9.81%
Coin of the day
Helium Helium
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Classifica tra le azioni #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Prezzo delle azioni
$9.50
Ultima sincronizzazione: 2025-01-08
Capitalizzazione di mercato
$819.52M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Poseida Therapeutics, Inc. (PSTX)

Categoria

Healthcare
Numero di azioni in circolazione per Poseida Therapeutics, Inc. (PSTX)
Numero di azioni in circolazione al September 2024: 97.16M
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Poseida Therapeutics, Inc., il numero attuale di azioni in circolazione è 97.16M. Alla fine del December 2022, la società aveva 71.91M azioni in circolazione. Il numero di azioni in circolazione è solitamente influenzato da split azionari e riacquisti.
Storico delle azioni in circolazione di Poseida Therapeutics, Inc. (PSTX) dal 2016 al 2026
Azioni in circolazione alla fine di ogni anno
Anno Azioni in circolazione Cambia
2026 (TTM) 97.16M 7.73%
2023 90.19M 25.41%
2022 71.91M 15.66%
2021 62.18M 6.47%
2020 58.40M 46.98%
2019 39.73M 10.59%
2018 35.93M -9.57%
2017 39.73M -33.01%
2016 59.32M 0.00%
Azioni in circolazione per aziende simili o concorrenti
Azienda Azioni in circolazione Differenza Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M 161.32%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -36.00%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M 392.91%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M 307.57%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH